183 related articles for article (PubMed ID: 20188102)
21. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
[TBL] [Abstract][Full Text] [Related]
22. Factors associated with the loss of response to infliximab in patients with Crohn's disease.
Sono K; Yamada A; Yoshimatsu Y; Takada N; Suzuki Y
Cytokine; 2012 Aug; 59(2):410-6. PubMed ID: 22633084
[TBL] [Abstract][Full Text] [Related]
23. The influence of infliximab and adalimumab on the expression of apoptosis-related proteins in lamina propria mononuclear cells and enterocytes in Crohn's disease - an immunohistochemical study.
Eder P; Lykowska-Szuber L; Krela-Kazmierczak I; Stawczyk-Eder K; Zabel M; Linke K
J Crohns Colitis; 2013 Oct; 7(9):706-16. PubMed ID: 23021876
[TBL] [Abstract][Full Text] [Related]
24. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
Gao Q; Hogezand RA; Lamers CB; Verspaget HW
Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
[TBL] [Abstract][Full Text] [Related]
25. Effect of tumor necrosis factor-α blockade on mucosal addressin cell-adhesion molecule-1 in Crohn's disease.
Biancheri P; Di Sabatino A; Rovedatti L; Giuffrida P; Calarota SA; Vetrano S; Vidali F; Pasini A; Danese S; Corazza GR; MacDonald TT
Inflamm Bowel Dis; 2013 Feb; 19(2):259-64. PubMed ID: 23328772
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab.
Papadakis KA; Shaye OA; Vasiliauskas EA; Ippoliti A; Dubinsky MC; Birt J; Paavola J; Lee SK; Price J; Targan SR; Abreu MT
Am J Gastroenterol; 2005 Jan; 100(1):75-9. PubMed ID: 15654784
[TBL] [Abstract][Full Text] [Related]
27. Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease--a possible target for infliximab treatment.
Agnholt J; Kelsen J; Brandsborg B; Jakobsen NO; Dahlerup JF
Eur J Gastroenterol Hepatol; 2004 Jul; 16(7):649-55. PubMed ID: 15201577
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease.
Assa A; Hartman C; Weiss B; Broide E; Rosenbach Y; Zevit N; Bujanover Y; Shamir R
J Crohns Colitis; 2013 Jun; 7(5):369-76. PubMed ID: 22483567
[TBL] [Abstract][Full Text] [Related]
29. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment.
Marits P; Landucci L; Sundin U; Davidsdottir L; Nilsson J; Befrits R; Wikström AC; Eberhardson M
J Crohns Colitis; 2014 Aug; 8(8):881-9. PubMed ID: 24486178
[TBL] [Abstract][Full Text] [Related]
30. Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease.
Di Sabatino A; Ciccocioppo R; Cupelli F; Cinque B; Millimaggi D; Clarkson MM; Paulli M; Cifone MG; Corazza GR
Gut; 2006 Apr; 55(4):469-77. PubMed ID: 16105889
[TBL] [Abstract][Full Text] [Related]
31. An increase in serum tumour necrosis factor-α during anti-tumour necrosis factor-α therapy for Crohn's disease - A paradox or a predictive index?
Eder P; Korybalska K; Łykowska-Szuber L; Stawczyk-Eder K; Krela-Kaźmierczak I; Łuczak J; Czepulis N; Linke K; Witowski J
Dig Liver Dis; 2016 Oct; 48(10):1168-71. PubMed ID: 27474201
[TBL] [Abstract][Full Text] [Related]
32. Anti-TNF-alpha antibody (infliximab) therapy supports the recovery of eNOS and VEGFR2 protein expression in endothelial cells.
Altorjay I; Veréb Z; Serfozo Z; Bacskai I; Bátori R; Erdodi F; Udvardy M; Sipka S; Lányi Á; Rajnavölgyi É; Palatka K
Int J Immunopathol Pharmacol; 2011; 24(2):323-35. PubMed ID: 21658307
[TBL] [Abstract][Full Text] [Related]
33. "In vitro" azathioprine-induced changes in peripheral T cell apoptosis and IFN-γ production associate with drug response in patients with Crohn's Disease.
Cossu A; Biancone L; Ascolani M; Pallone F; Boirivant M
J Crohns Colitis; 2013 Jul; 7(6):441-50. PubMed ID: 22840925
[TBL] [Abstract][Full Text] [Related]
34. Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn's disease treated with anti-TNF antibodies.
Katz LH; Kopylov U; Fudim E; Yavzori M; Picard O; Ungar B; Eliakim R; Ben-Horin S; Chowers Y
Clin Res Hepatol Gastroenterol; 2014 Sep; 38(4):491-8. PubMed ID: 24613656
[TBL] [Abstract][Full Text] [Related]
35. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.
Baert FJ; D'Haens GR; Peeters M; Hiele MI; Schaible TF; Shealy D; Geboes K; Rutgeerts PJ
Gastroenterology; 1999 Jan; 116(1):22-8. PubMed ID: 9869598
[TBL] [Abstract][Full Text] [Related]
36. Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease.
Noth R; Stüber E; Häsler R; Nikolaus S; Kühbacher T; Hampe J; Bewig B; Schreiber S; Arlt A
J Crohns Colitis; 2012 May; 6(4):464-9. PubMed ID: 22398062
[TBL] [Abstract][Full Text] [Related]
37. Impact of infliximab on serum leptin levels in patients with Crohn's disease.
Franchimont D; Roland S; Gustot T; Quertinmont E; Toubouti Y; Gervy MC; Deviere J; Van Gossum A
J Clin Endocrinol Metab; 2005 Jun; 90(6):3510-6. PubMed ID: 15784704
[TBL] [Abstract][Full Text] [Related]
38. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
[TBL] [Abstract][Full Text] [Related]
39. The Sushi domain of soluble IL-15 receptor alpha is essential for binding IL-15 and inhibiting inflammatory and allogenic responses in vitro and in vivo.
Wei Xq ; Orchardson M; Gracie JA; Leung BP; Gao Bm ; Guan H; Niedbala W; Paterson GK; McInnes IB; Liew FY
J Immunol; 2001 Jul; 167(1):277-82. PubMed ID: 11418660
[TBL] [Abstract][Full Text] [Related]
40. Soluble Interleukin IL-15Ralpha is generated by alternative splicing or proteolytic cleavage and forms functional complexes with IL-15.
Bulanova E; Budagian V; Duitman E; Orinska Z; Krause H; Rückert R; Reiling N; Bulfone-Paus S
J Biol Chem; 2007 May; 282(18):13167-79. PubMed ID: 17327231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
